Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZN-825 in Idiopathic Pulmonary Fibrosis
2023-509784-24-00Phase 2Completed
- Sponsor
- Horizon Therapeutics
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing HZN-825 with Placebo (2 arms). Primary endpoints: Change in FVC % predicted from Baseline to Week 52 (Core Phase) and Change from both Baselines in FVC % predicted at Week 104 (Extension Phase). Started May 2024; status: completed.
02
Drugs
fipaxalparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2023-509784-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509784-24-00.